Synapse - Works

Results (30)

RAIN (Renal AL amyloid Involvement and NEOD001): A multicenter, randomized, phase 2b study of NEOD001 in previously treated subjects with systemic AL amyloidosis and persistent renal involvement

Meeting Abstract

Varga, C.; Dispenzieri, A.; Gertz, M. A.; Goodman, S. A.; Hsu, K.; Inker, L.; Landau, H.; Leung, N.; Mikhael, J. R.; Sher, T.; more...
Blood (2017)

Fulltext@MSK | Save

Romiplostim for chemotherapy-induced thrombocytopenia (CIT). Results of a phase 2 trial

Meeting Abstract

Soff, G. A.; Miao, Y.; Devlin, S. M.; Mantha, S.; Mones, J. V.; Li, V. J.; Abou-Alfa, G. K.; Cercek, A.; Kemeny, N.; Parameswaran, R.
Blood (2017)

Fulltext@MSK | Save

Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)

Meeting Abstract

Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
Blood (2017)

Fulltext@MSK | Save

Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with autologous hematopoietic stem cell transplant (AHCT) for multiple myeloma and AL amyloidosis

Meeting Abstract

Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S. J.; Devlin, S. M.; Chung, D. J.; Dahi, P. B.; more...
Blood (2017)

Fulltext@MSK | Save

Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study

Meeting Abstract

Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; McMillan, A. K.; Kim, T. M.; Kim, W. S.; Hertzberg, M.; Ozcan, M.; Penuel, E.; more...
Blood (2017)

Fulltext@MSK | Save

Adoptive T-cell therapy with 3rd party CMV-pp65-specific CTLs for CMV viremia and disease arising after allogeneic hematopoietic stem cell transplant

Meeting Abstract

Prockop, S.; Doubrovina, E.; Rodriguez-Sanchez, I.; Hasan, A. N.; Barker, J.; Castro-Malaspina, H. R.; Dahi, P. B.; Giralt, S. A.; Gyurkocza, B.; Kernan, N. A.; more...
Blood (2017)

Fulltext@MSK | Save

Long-term follow-up of adult double unit cord blood (CB) transplantation (dCBT) recipients reveals high rates of progression-free survival after a novel cy/flu/thio/TBI 400 intermediate intensity conditioning regimen

Meeting Abstract

Politikos, I.; Devlin, S. M.; Jacob, A.; Maloy, M.; Mazis, C.; Naputo, K.; Scaradavou, A.; O'Reilly, R.; Avecilla, S.; Castro-Malaspina, H. R.; more...
Blood (2017)

Fulltext@MSK | Save

More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (Allo-HCT)

Meeting Abstract

Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
Blood (2017)

Fulltext@MSK | Save

Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis

Meeting Abstract

Mehta-Shah, N.; Teja, S.; Tao, Y.; Cashen, A. F.; Beaven, A.; Alpdogan, O.; Porcu, P.; Wiggin, M.; Song, K. W.; Alzahrani, M.; more...
Blood (2017)

Fulltext@MSK | Save

A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
Blood (2017)

Fulltext@MSK | Save